Factor This Power Engineering
Live Events
DTECH® Events
POWERGENâ¢
Calendar
Webinars
Podcasts
Contribute Content
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Smart Grids
Transmission
Hydropower
Dams & Civil Structures
Small Hydropower
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Project Development
Tariffs
Electric Vehicles
EV Charging
Vehicle to Grid
Subscribe
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Transmission
Smart Grids
Hydropower
Dams & Civil Structures
Small Hydro
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Electric Vehicles
EV Charging
Vehicle to Grid
Factor This: Power Engineering
Live Events
DISTRIBUTECH®
Podcasts
Webinars
Calendar
Contribute Content
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Royalty Pharma plc - Class A Ordinary Shares
(NQ:
RPRX
)
46.47
+0.12 (+0.26%)
Streaming Delayed Price
Updated: 10:34 AM EDT, Mar 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Royalty Pharma plc - Class A Ordinary Shares
< Previous
1
2
3
4
5
Next >
Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases
Today 7:15 EDT
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence
March 23, 2026
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Announces Expansion of Leadership Team
March 17, 2026
Greg Butz joins Royalty Pharma as Executive Vice President, Partnering & Investments
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform
March 02, 2026
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing
March 02, 2026
From
Royalty Pharma plc
Via
GlobeNewswire
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
March 02, 2026
From
Zymeworks Inc.
Via
GlobeNewswire
Royalty Pharma to Present at TD Cowen’s 46th Annual Health Care Conference
February 26, 2026
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Reports Q4 and Full Year 2025 Results
February 11, 2026
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
January 20, 2026
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference
January 12, 2026
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
January 11, 2026
From
Royalty Pharma plc
Via
GlobeNewswire
Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
January 11, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Royalty Pharma Announces Dividend Increase
January 09, 2026
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones
December 29, 2025
Royalty Pharma will now own 100% of the 8% to 16% Evrysdi royalty following multiple transactions with PTC since 2020
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million
December 16, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement
December 04, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
December 04, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Royalty Pharma to Present at Upcoming Investor Conferences
November 26, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Reports Third Quarter 2025 Results
November 05, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Acquires Royalty Interest in Alnylam’s AMVUTTRA for $310 Million from Blackstone Life Sciences
November 04, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Declares Fourth Quarter 2025 Dividend
October 17, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025
October 09, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director
September 29, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Present at Bernstein’s 2nd Annual Healthcare Forum
September 19, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company’s Plans to Drive Value Creation
September 11, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Announces Release of Deloitte’s Report on the Biopharma Royalty Market
September 10, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
September 04, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes
September 02, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million
September 02, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million
September 02, 2025
From
Zenas BioPharma
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
